Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Abbott, Biotest AG Partner on RA and Psoriasis Treatment

June 21, 2011 11:43 am | News | Comments

Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.


Study Reveals How Immune System Responds to Hepatitis A

June 21, 2011 11:37 am | News | Comments

A study by a team from the Texas Biomedical Research Institute comparing hepatitis C virus (HCV) with hepatitis A virus (HAV) infections in chimpanzees sheds light on the nature of the body's immune response to these viruses.


Study Shows Vismodegib Helps Shrink Tumors

June 21, 2011 11:31 am | News | Comments

Genentech announced a Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.


Scripps Team Explains How Blood Clots Form

June 21, 2011 11:25 am | News | Comments

Scripps Research Institute scientists have discovered new elements of the blood clot-formation process that could lead to better drugs for preventing heart attacks and other clot-related conditions.


Medidata to Acquire Clinical Force

June 21, 2011 8:29 am | News | Comments

Medidata Solutions, a global provider of SaaS-based clinical development solutions, agreed to acquire Clinical Force, a pioneer in providing SaaS-based clinical trial management systems.


Liquid Handling

June 21, 2011 8:18 am | Product Releases | Comments

Redd&Whyte is launching the Preddator 4-channel system. The S4 has four dispensing channels for more efficient microplate filling and contains a number of enhancements to its software.


Gas Addition Module

June 21, 2011 8:13 am | Product Releases | Comments

Uniqsis Ltd is introducing a gas addition module for the Uniqsis FlowSyn and other continuous flow reactors. The new module enables fast, controllable pre-saturation of liquid reagents with a wide range of gases.


Smart Materials Help in Forming Crystals

June 21, 2011 7:52 am | News | Comments

Scientists have developed a method to make proteins form crystals using "smart materials" that remember the shape and characteristics of the molecule. This new technique should help scientists work out the structure of drug targets.


Seaside Begins Arbaclofen Trial

June 21, 2011 7:42 am | News | Comments

Seaside Therapeutics, Inc. initiated a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 on social impairment in children, adolescents, and adults with autism spectrum disorders.


GSK Sues Watson Over Avodart

June 21, 2011 7:36 am | News | Comments

Watson Pharmaceuticals Inc. is seeking Food and Drug Administration approval to sell a generic version of GlaxoSmithKline's enlarged-prostate treatment Avodart, the drugmaker said.


New Treatment for Cystic Fibrosis Developed

June 21, 2011 7:33 am | News | Comments

An international research team has developed a groundbreaking treatment for cystic fibrosis sufferers. The new drug will benefit sufferers who have the 'Celtic Gene', a genetic mutation which is particularly common in Ireland.


Generic Levaquin Approved By FDA

June 21, 2011 7:28 am | News | Comments

The Food and Drug Administration said it approved the first generic versions of Johnson & Johnson's antibiotic Levaquin, which treats bacterial infections that cause bronchitis or pneumonia.


EU Approves Bydureon

June 21, 2011 7:25 am | News | Comments

European Union regulators have approved the first once-per-week diabetes medication. Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said they received marketing approval for Bydureon.


Sanofi-Aventis and Audion Partnership

June 20, 2011 12:53 pm | News | Comments

SanofiAventis said on June 16 it will work with Audion Therapeutics to develop therapies that could restore hearing loss.


ReNeuron Signs Agreement With Eye Research for Retina Diseases

June 20, 2011 12:49 pm | News | Comments

ReNeuron Group announces it signed a patent and license agreement with Schepens Eye Research Institute regarding the company’s ReN003 stem cell therapy program focused on diseases of the retina.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.